

Audit Review Table					
Presbyterian Health Plan, Inc. (Org ID: 579, Sub ID: 4104, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2024; Date & Timestamp - 6/10/2025 3:06:25 PM					
This submission is on the stage: Submission Finalized					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
BMI percentile (Total)		61.81%	R	R	Reported
Counseling for Nutrition (Total)		24.13%	R	R	Reported
Counseling for Physical Activity (Total)		26.18%	R	R	Reported
Childhood Immunization Status (CIS)					
DTaP		73.43%	R	R	Reported
IPV		86.91%	R	R	Reported
MMR		86.81%	R	R	Reported
HiB		85.53%	R	R	Reported
Hepatitis B		88.53%	R	R	Reported
VZV		86.21%	R	R	Reported
Pneumococcal Conjugate		72.68%	R	R	Reported
Hepatitis A		86.60%	R	R	Reported
Rotavirus		73.55%	R	R	Reported
Influenza		34.54%	R	R	Reported
Combo 3		66.31%	R	R	Reported
Combo 7		60.19%	R	R	Reported
Combo 10		27.87%	R	R	Reported
Immunizations for Adolescents (IMA)					
Meningococcal		83.70%	R	R	Reported
Tdap		84.67%	R	R	Reported
HPV		37.47%	R	R	Reported
Combination 1		82.97%	R	R	Reported
Combination 2		36.74%	R	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children		42.09%	R	R	Reported
Cervical Cancer Screening (CCS)					
Cervical Cancer Screening		44.27%	R	R	Reported
Chlamydia Screening in Women (CHL)					
(Total)		47.49%	R	R	Reported
Oral Evaluation, Dental Services (OED)	Y				
(0-2)		31.33%	R	R	Reported
(3-5)		63.36%	R	R	Reported
(6-14)		65.24%	R	R	Reported
(15-20)		44.57%	R	R	Reported
(Total)		55.03%	R	R	Reported
Topical Fluoride for Children (TFC)					
(1-2)		8.90%	R	R	Reported
(3-4)		10.73%	R	R	Reported
(Total)		9.83%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)	Y				
(Total)		82.43%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)	Y				
Systemic Corticosteroid		58.73%	R	R	Reported
Bronchodilator		70.13%	R	R	Reported
Asthma Medication Ratio (AMR)	Y				
(Total)		74.12%	R	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		44.03%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	Y				
Persistence of Beta-Blocker Treatment After a Heart Attack		56.92%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)	Y				
Received Statin Therapy (Total)		65.11%	R	R	Reported
Statin Adherence 80% (Total)		76.00%	R	R	Reported
Cardiac Rehabilitation (CRE)					
Initiation (Total)		2.71%	R	R	Reported

Engagement1 (Total)		3.33%	R	R	Reported
Engagement2 (Total)		4.17%	R	R	Reported
Achievement (Total)		0.63%	R	R	Reported
<b>Glycemic Status Assessment for Patients With Diabetes (GSD)</b>					
Glycemic Status <8.0%		50.36%	R	R	Reported
Glycemic Status >9.0%		41.12%	R	R	Reported
<b>Blood Pressure Control for Patients With Diabetes (BPD)</b>					
Blood Pressure Control for Patients With Diabetes		46.04%	R	R	Reported
<b>Eye Exam for Patients With Diabetes (EED)</b>					
Eye Exam for Patients With Diabetes		52.31%	R	R	Reported
<b>Kidney Health Evaluation for Patients With Diabetes (KED)</b>					
(Total)		35.93%	R	R	Reported
<b>Statin Therapy for Patients With Diabetes (SPD)</b>	Y				
Received Statin Therapy		51.36%	R	R	Reported
Statin Adherence 80%		69.75%	R	R	Reported
<b>Diagnosed Mental Health Disorders (DMH)</b>					
(Total)		28.92%	R	R	Reported
<b>Antidepressant Medication Management (AMM)</b>	Y				
Effective Acute Phase Treatment		71.32%	R	R	Reported
Effective Continuation Phase Treatment		58.83%	R	R	Reported
<b>Follow-Up After Hospitalization for Mental Illness (FUH)</b>	Y				
30 days (Total)		56.47%	R	R	Reported
7 days (Total)		36.34%	R	R	Reported
<b>Follow-Up After Emergency Department Visit for Mental Illness (FUM)</b>	Y				
30 days (Total)		48.53%	R	R	Reported
7 days (Total)		31.49%	R	R	Reported
<b>Diagnosed Substance Use Disorders (DSU)</b>					
Alcohol (Total)		4.71%	R	R	Reported
Opioid (Total)		4.24%	R	R	Reported
Other (Total)		5.41%	R	R	Reported
Any (Total)		10.78%	R	R	Reported
<b>Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)</b>	Y				
30 days (Total)		48.90%	R	R	Reported
7 Days (Total)		26.26%	R	R	Reported
<b>Follow-Up After Emergency Department Visit for Substance Use (FUA)</b>	Y				
30 days (Total)		35.57%	R	R	Reported
7 days (Total)		23.76%	R	R	Reported
<b>Pharmacotherapy for Opioid Use Disorder (POD)</b>	Y				
(Total)		23.51%	R	R	Reported
<b>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)</b>	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		82.74%	R	R	Reported
<b>Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)</b>					
Diabetes Monitoring for People With Diabetes and Schizophrenia		68.46%	R	R	Reported
<b>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)</b>					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia		71.43%	R	R	Reported
<b>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)</b>	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		56.60%	R	R	Reported
<b>Appropriate Treatment for Upper Respiratory Infection (URI)</b>	Y				
(Total)		85.70%	R	R	Reported
<b>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)</b>	Y				
(Total)		63.17%	R	R	Reported
<b>Use of Imaging Studies for Low Back Pain (LBP)</b>					
(Total)		69.88%	R	R	Reported
<b>Use of Opioids at High Dosage (HDO)</b>	Y				
Use of Opioids at High Dosage		3.50%	R	R	Reported

<b>Use of Opioids From Multiple Providers (UOP)</b>	Y				
<i>Multiple Prescribers</i>		13.89%	R	R	Reported
<i>Multiple Pharmacies</i>		1.44%	R	R	Reported
<i>Multiple Prescribers and Multiple Pharmacies</i>		0.82%	R	R	Reported
<b>Risk of Continued Opioid Use (COU)</b>	Y				
<i>&gt;=15 Days (Total)</i>		6.73%	R	R	Reported
<i>&gt;=31 Days (Total)</i>		4.40%	R	R	Reported
<b>Access/Availability of Care</b>					
<b>Adults' Access to Preventive/Ambulatory Health Services (AAP)</b>					
<i>(Total)</i>		75.46%	R	R	Reported
<b>Initiation and Engagement of Substance Use Disorder Treatment (IET)</b>	Y				
<i>Initiation of SUD Treatment - Total (Total)</i>		50.77%	R	R	Reported
<i>Engagement of SUD Treatment - Total (Total)</i>		19.85%	R	R	Reported
<b>Prenatal and Postpartum Care (PPC)</b>					
<i>Timeliness of Prenatal Care</i>		72.27%	R	R	Reported
<i>Postpartum Care</i>		71.34%	R	R	Reported
<b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)</b>	Y				
<i>(Total)</i>		60.56%	R	R	Reported
<b>Utilization and Risk Adjusted Utilization</b>					
<b>Well-Child Visits in the First 30 Months of Life (W30)</b>					
<i>(First 15 Months)</i>		66.50%	R	R	Reported
<i>(15 Months-30 Months)</i>		70.82%	R	R	Reported
<b>Child and Adolescent Well-Care Visits (WCV)</b>					
<i>(Total)</i>		47.51%	R	R	Reported
<b>Antibiotic Utilization for Respiratory Conditions (AXR)</b>	Y				
<i>(Total)</i>		25.98%	R	R	Reported
<b>Plan All-Cause Readmissions (PCR)</b>			R	R	Reported
<b>Health Plan Descriptive Information</b>					
<b>Enrollment by Product Line (ENP)</b>			R	R	Reported
<b>Language Diversity of Membership (LDM)</b>			R	R	Reported
<b>Race/Ethnicity Diversity of Membership (RDM)</b>			R	R	Reported
<b>Measures Reported Using Electronic Clinical Data Systems</b>					
<b>Childhood Immunization Status (CIS-E)</b>					
<i>DTaP</i>		73.43%	R	R	Reported
<i>IPV</i>		86.91%	R	R	Reported
<i>MMR</i>		86.81%	R	R	Reported
<i>HIB</i>		85.53%	R	R	Reported
<i>Hepatitis B</i>		88.53%	R	R	Reported
<i>VZV</i>		86.21%	R	R	Reported
<i>Pneumococcal Conjugate</i>		72.68%	R	R	Reported
<i>Hepatitis A</i>		86.60%	R	R	Reported
<i>Rotavirus</i>		73.55%	R	R	Reported
<i>Influenza</i>		34.54%	R	R	Reported
<i>Combo 3</i>		66.31%	R	R	Reported
<i>Combo 7</i>		60.19%	R	R	Reported
<i>Combo 10</i>		27.87%	R	R	Reported
<b>Immunizations for Adolescents (IMA-E)</b>					
<i>Meningococcal</i>		84.39%	R	R	Reported
<i>Tdap</i>		85.63%	R	R	Reported
<i>HPV</i>		36.60%	R	R	Reported
<i>Combination 1</i>		83.52%	R	R	Reported
<i>Combination 2</i>		35.91%	R	R	Reported
<b>Breast Cancer Screening (BCS-E)</b>					
<i>Breast Cancer Screening</i>		42.15%	R	R	Reported
<b>Cervical Cancer Screening (CCS-E)</b>					
<i>Cervical Cancer Screening</i>		44.27%	R	R	Reported
<b>Colorectal Cancer Screening (COL-E)</b>					
<i>(Total)</i>		33.91%	R	R	Reported
<b>Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)</b>	Y				
<i>Initiation Phase</i>		43.81%	R	R	Reported
<i>Continuation and Maintenance Phase</i>		53.40%	R	R	Reported

<b>Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)</b>	Y				
<i>Blood Glucose Testing (Total)</i>		61.37%	R	R	Reported
<i>Cholesterol Testing (Total)</i>		39.75%	R	R	Reported
<i>Blood Glucose and Cholesterol Testing (Total)</i>		39.40%	R	R	Reported
<b>Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)</b>					
<i>Depression Screening (Total)</i>		16.80%	R	R	Reported
<i>Follow-Up on Positive Screen (Total)</i>		75.87%	R	R	Reported
<b>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)</b>					
<i>Utilization of PHQ-9-Total (Total)</i>		9.55%	R	R	Reported
<b>Depression Remission or Response for Adolescents and Adults (DRR-E)</b>					
<i>Follow-Up PHQ-9 (Total)</i>		46.47%	R	R	Reported
<i>Depression Remission (Total)</i>		15.45%	R	R	Reported
<i>Depression Response (Total)</i>		21.19%	R	R	Reported
<b>Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)</b>					
<i>Unhealthy Alcohol Use Screening (Total)</i>		0.00%	R	R	Reported
<i>Alcohol Counseling or Other Follow-Up Care (Total)</i>			NA	R	Reported
<b>Adult Immunization Status (AIS-E)</b>					
<i>Influenza (Total)</i>		19.20%	R	R	Reported
<i>Td/Tdap (Total)</i>		51.64%	R	R	Reported
<i>Zoster (Total)</i>		21.04%	R	R	Reported
<i>Pneumococcal (66+)</i>		70.06%	R	R	Reported
<b>Prenatal Immunization Status (PRS-E)</b>					
<i>Influenza</i>		33.95%	R	R	Reported
<i>Tdap</i>		68.93%	R	R	Reported
<i>Combination</i>		30.72%	R	R	Reported
<b>Prenatal Depression Screening and Follow-Up (PND-E)</b>					
<i>Depression Screening</i>		37.04%	R	R	Reported
<i>Follow-Up on Positive Screen</i>		46.24%	R	R	Reported
<b>Postpartum Depression Screening and Follow-Up (PDS-E)</b>					
<i>Depression Screening</i>		19.85%	R	R	Reported
<i>Follow-Up on Positive Screen</i>		59.46%	R	R	Reported
<b>Social Need Screening and Intervention (SNS-E)</b>					
<i>Food Screening (Total)</i>		0.00%	R	R	Reported
<i>Food Intervention (Total)</i>			NA	R	Reported
<i>Housing Screening (Total)</i>		0.00%	R	R	Reported
<i>Housing Intervention (Total)</i>			NA	R	Reported
<i>Transportation Screening (Total)</i>		0.00%	R	R	Reported
<i>Transportation Intervention (Total)</i>			NA	R	Reported